- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- Join Join
In The May Issue
- New ASA Partnership to Support Patients’ Rights
- Federal Government Drops Dispensary Cases
- State Dept. Says DEA Can License More to Grow Cannabis
- Patient Groups Urge DEA to Reschedule Cannabis
- State Medical Cannabis Program Developments
- California Citizen Lobby Day May 23
- ASA Activist Profile: Georgia Action Group
New ASA Partnership to Support Patients’ Rights
Americans for Safe Access and Orrick, Herrington & Sutcliffe LLP, a global legal powerhouse based in San Francisco, announced last month a new partnership to provide no-cost legal support to medical cannabis patients through ASA’s Patients’ Rights Project.
For more than a decade, ASA’s Patients’ Rights Project has helped medical cannabis stakeholders navigate the often confusing legal landscape, providing educational materials, advocating for better legislation, and working through the courts.
The partnership project will include new legal manuals for patients and guides for public defenders who represent them in court. In the fall, Orrick will begin coordinating attorneys to support ASA’s legal hotline for individual patients and monitor implementation of state medical cannabis programs.
Each of the dozens of state medical cannabis laws is unique, as are those in the District of Columbia, Guam and Puerto Rico. What counts as compliance with those laws is often decided by court cases, and confusion over what is allowed often leaves patients and providers vulnerable to arrest, prosecution, and incarceration.
“Partnering with Orrick on this important project will allow us to keep up with demand,” said Steph Sherer, ASA’s Executive Director. “With over two million medical cannabis patients and rapidly evolving laws, the services the Patient's Rights Project provides have never been more important.”
Orrick, founded in San Francisco a century and a half ago, today has global reach through 25 offices and a reputation for dedicated pro bono work on diverse causes, including immigration, civil rights, systemic problems and grassroots global development.
“We are very excited to start a pro bono relationship with such a dynamic nonprofit, as Americans for Safe Access,” said Rene Kathawala, Orrick’s pro bono counsel. ”They offer first-rate advocacy in ensuring that low-income patients with a medical need for cannabis have the legal and other necessary support.”
Over the last 14 years, ASA has helped thousands of patients with legal support through their toll-free patient hotline, online interactive FAQ, and one-on-one visits with patients and other stakeholders. Changing laws have reduced, but not eliminated, criminal sanctions and prosecutions of legal medical cannabis patients and others. However, patients still face pervasive discrimination in employment, access to health care, housing, and parental rights. They also face inappropriate harassment and prosecution.
“ASA anticipates that the support provided by Orrick will be increasingly significant as medical cannabis laws continue to be adopted, amended, and implemented nationwide” continued Sherer. “This type of professional help and capacity is needed to protect patients and providers, identify opportunities to expand their rights, and inform policymakers about the challenges that remain.”
Federal Government Drops Dispensary Cases
The Department of Justice (DOJ) may finally be accepting the restrictions Congress placed on medical cannabis enforcement in 2014. Last month, prosecutors abandoned two civil cases targeting California dispensaries, following a federal court ruling last October that the Rohrabacher-Farr Amendment to the DOJ budget blocks such cases.
Early in April, the DOJ dropped their appeal of that ruling on the 14-year-old injunction that eventually shut the Marin Alliance for Medical Marijuana (MAMM), and later in the month they also dropped their asset forfeiture suit against Harborside Health Center in Oakland.
The case against Harborside, the largest dispensary in the nation, was brought by the DOJ back in 2011 as part of a broad federal strategy of using asset forfeiture threats against landlords who rented to licensed medical cannabis businesses. The strategy was successful in closing hundreds of dispensaries in California and elsewhere.
The Harborside case was different from most in that the operators and landlord contested the action and were joined in the court battle by the City of Oakland, which argued it had a right to regulate and tax the business without interference from federal authorities.
"We celebrate the release from federal prosecution," said Oakland Mayor Libby Schaaf at a press conference announcing the deal. "We believe in compassion; we believe in health."
The government’s decision was reportedly, at least in part, a direct result of the Rohrabacher-Farr Amendment to the 2016 budget, which says the DOJ cannot spend any money on interfering with state medical cannabis programs. The DOJ has argued that the amendment does not restrict civil suits and criminal prosecutions of individuals or businesses. ASA was among those who demonstrated the amendment's intent and proper application prevents just such enforcement actions, which US District Judge Charles Breyer ultimately affirmed.
“We congratulate Harborside and their lawyer, Henry Wykowski, for their perseverance in getting the feds to drop this case,” said ASA Government Affairs Director Mike Liszewski. “The Harborside and MAMM victories are proof that the Rohrabacher-Farr Amendment was not merely symbolic.”
ASA worked for more than a decade through six House votes before getting it passed the first time in 2014, and again in 2015. As a budget rider, the amendment must be renewed each year. A durable solution to the federal crackdown on state medical cannabis programs will most likely come through direct legislation, such as the CARERS Act.
State Dept. Says DEA Can License More to Grow Cannabis
The US State Department has gone on record that the Drug Enforcement Administration (DEA) may issue more licenses to cultivate research cannabis. The DEA has long maintained that the monopoly on research cannabis production held by the National Institute on Drug Abuse (NIDA) was the only way to comply with international treaties.
Legal analysis by the Bureau of International Narcotics and Law Enforcement at the State Department concluded otherwise, finding that the United Nations Single Convention on Narcotic Drugs does not prohibit multiple licenses for the cultivation of cannabis for medical and scientific purposes. The State Department finding came in response to an inquiry from Senator Kirsten Gillibrand (D-NY).
“For years, the DEA has cited this international treaty as the reason for limiting medical research,” said Sen. Gillibrand in a statement. “Now that the State Department has confirmed this treaty should not be a barrier to expanding research, the DEA should issue new licenses to supply medical researchers and stop letting antiquated ideology stand in the way of modern medical science.”
Currently, the only licensed cultivation facility is at the University of Mississippi. Researchers have complained for years that the facility does not provide sufficient amounts or appropriate types for research. In 2013 a DEA administrative law judge issued a ruling that allowing more licenses was in the public interest, and NIDA itself went on record before Congress last year recommending their monopoly be discontinued.
“Marijuana is the only schedule I drug that requires a single government enforced monopoly for access to study it,” said Dr. Sue Sisley, a PTSD researcher who has been unable to obtain research cannabis for her approved study. “This monopoly has proven over and over again that they are incompetent and incapable of providing the various strains that are requested by scientists in a timely manner.”
Several other countries have issued multiple licenses to grow cannabis for medical and scientific purposes, and none have faced UN sanctions. Canada and Holland have issued multiple licenses for not only research studies but also producing medicine for patients.
“President Obama should direct the DEA to immediately begin the process of issuing additional licenses,” said Mike Liszewski, ASA’s Director of Government Affairs. “Breaking up the DEA-mandated NIDA monopoly would benefit researchers and patients alike, and would not offend treaty obligations.”
Patient Groups Urge DEA to Reschedule Cannabis
The Epilepsy Foundation is urging the Drug Enforcement Administration (DEA) to remove barriers to medical cannabis in a group letter signed by a coalition of patient organizations, including Americans for Safe Access.
The April 28 letter came in response to an announcement from three federal agencies that the government would issue a determination this year on how cannabis is classified. The DEA, the Department of Health and Human Services (HHS), and the Office of National Drug Control Policy (ONDCP) issued the joint announcement in response to an inquiry from seven US Senators, including two of the original sponsors of the CARERS Act, Cory Booker and Kirsten Gillibrand.
The letter from the Epilepsy Foundation, ASA, and other patient organizations to DEA Acting Administrator Chuck Rosenberg notes that “[m]oving cannabis from Schedule I in the Controlled Substances Act would lift federal barriers to research on cannabis, which would ultimately lead to new treatments as well as much needed information that can help families make informed choices about medical cannabis.”
In addition to the Epilepsy Foundation and ASA, some of the organizations that signed the letter are:
- Citizens United for Research in Epilepsy (CURE)
- Danny Did Foundation Finding a Cure Against Epilepsy
- Langone Medical Center
- Hope for Harper Hope for Hypothalamic Hamartomas
- International Foundation for CDKL5
- Lennox Gastaut Syndrome (LGS) Foundation
- National Multiple Sclerosis Society
- Parkinson’s Action Network
- Phelan-McDermid Syndrome Foundation
- Ring14 USA Outreach
- The AIDS Alliance
- The Brain Recovery Project
- Tuberous Sclerosis Alliance
Text of the Epilepsy Foundation’s group letter
State Medical Cannabis Program Developments
The Connecticut legislature late last month passed a bill that will allow patients under the age of 18 to have access to medical cannabis products. HB 5450 will allow pediatric patients access to medical cannabis edibles and extracts with a recommendation from two physicians. The bill also authorizes the Department of Consumer Protection to regulate laboratory testing of cannabis and approve research studies. Governor Dan Malloy is expected to sign the bill.
In New Hampshire, the first medical cannabis dispensary began serving patients last month, nearly three years since the state’s medical cannabis law went into effect. The Sanctuary Alternative Treatment Center in Plymouth is expecting nearly 1,000 patients, and four other licensed dispensaries are planning to open later this year.
In Hawaii, the Department of Health has chosen eight companies to cultivate and distribute medical cannabis. Each selected company will be allowed two cultivation and two dispensing locations, which may open in July. One of the firms that was selected, Manoa Botanicals, is currently pre-certified for ASA's Patient Focused Certification (PFC) program. PFC will work with Manoa to help ensure patients in Hawaii are able to obtain the highest quality medicine available.
California Citizen Lobby Day May 23
ASA’s fifth annual California Citizen Lobby Day will be held in Sacramento on Monday, May 23. Advocates have a chance to join 300 other patients and advocates to talk face-to-face with lawmakers and regulators about medical cannabis in California. ASA will provide lobbying materials and arrange meetings with the elected representatives in the Senate and Assembly for all who register. At the end of the day, ASA will host a VIP Reception with lawmakers and other citizen lobbyists.
Lobby Day begins with a continental breakfast and citizen lobbyist training at the Hyatt Regency Hotel on L Street, right across the street from the state Capitol Building. Lobby day participants will also receive a special legislative briefing from the new chief of the state’s Bureau of Medical Marijuana Regulation, Lori Ajax, and the bureau’s Senior Policy Advisor, An-Chi Tsou. The two officials will discuss the implementation of the new Medical Marijuana Regulation and Safety Act (MMRSA).
Among the legislation to be lobbied for is an ASA proposal for a 2017 bill that would protect medical cannabis patients from discrimination in employment, parental rights, housing, and access to health care. ASA is opposing two bills this year that would impose excessive taxation on medical cannabis consumption and cultivation. Other pending bills would make changes in the way that commercial medical cannabis businesses and organizations are licensed and regulated.
The suggested donation for the lobby day is $40, but no one will be turned away for lack of funds. Click here to register for the California Citizen Lobby Day on Monday, May 23, and ASA will make an appointment for you at your State Assembly and Senate offices.
ASA Activist Profile: Georgia Action Group
Among those honored at ASA’s annual Awards Dinner at the 2016 Unity Conference was the ASA Action Group of the Year, Georgia’s Hope. The group was recognized for playing an instrumental part in advancing safe access in their state, with new legislation passed last year to protect qualified patients with eight medical conditions.
Georgia’s Hope came together in late 2013 when two parent groups, one for children with seizures and one for kids with mitochondrial disorder, separately approached ASA for support after seeing Sanjay Gupta’s medical cannabis documentary on CNN. Once ASA put the two groups in touch with each other, they committed to working together and established themselves as an ASA Action Group in early 2014.
The first step was reaching out to their state legislators and the media, but they didn’t expect to get much attention. Yet immediately that work resulted in the Atlanta ABC station airing a segment with local families of children with intractable seizures that might be helped by medical cannabis, followed a few days later by an on-air interview with Janea Cox and her four-year-old daughter Haleigh, who would become the namesake of the state’s medical cannabis law.
After State Rep. Allen Peake (R-Macon) met Haleigh Cox in the hospital, he reached out to the ASA group asking to meet. Within just a few weeks, Rep. Peake had introduced with five co-sponsors a limited medical cannabis bill. HB 885, also called Haleigh’s Hope Act, passed the House 171 to 4 but was denied a vote in the Senate by political maneuvering. As a result, many families, including Janea and Haleigh Cox, moved to other states to access cannabis treatment.
In 2015, Rep. Peake tried again, introducing HB 1 to allow cannabis oil with up to 5% THC for eight qualifying conditions. The bill passed and was signed by Gov. Nathan Deal in April, but with no mechanism in the law to produce or acquire medicine, Georgia’s Hope was committed to passing a more comprehensive medical cannabis program.
“We will work until we get something,” said Sebastien Cotte, one of the leaders of Georgia’s Hope whose son Jagger has mitochondrial disease. “It is not just for our kids, but for all patients.”
In 2016, the Georgia’s Hope, Facebook page grew to more than 16,000 followers. They teamed up with another group, Hope United, to get support from more people representing other conditions.
A new bill introduced by Peake this year, HB 722, would have established an in-state cultivation and distribution program, added more qualifying conditions, and removed the THC limit. The bill had support in the House, but opposition from Gov. Deal forced Peale to scale it back to an expansion of qualifying conditions. The stripped-down bill passed the House with overwhelming support but did not get a committee hearing in the Senate, despite patient lobbying into the final minutes of the session (pictured at left).
“We thought we had a good but still very conservative bill with a lot of support from our legislators,” said Shannon Cloud, another active member of Georgia’s Hope “It was very discouraging to find out that it didn’t have a chance once the governor said before session even started he would not support it. We will not give up until all patients have access.”
Georgia’s Hope Facebook page
ACTION ALERT: Demand Action on CARERS from Sen. Grassley
The Compassionate Access, Research Expansion, and Respect States Act (CARERS) keeps gathering Senate co-sponsors but remains stuck in committee. Urge Sen. Chuck Grassley to give the CARERS Act a hearing in the Judiciary Committee so your Senators can vote on the most comprehensive federal medical cannabis legislation ever introduced. Call his office today at (202) 224-3744.
Get the PDF Version to Print and Distribute
Download a printable copy of this Newsletter